Physician profile
Michael R Banton
NPI 1619984523
$3,326.98
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $411 · 2021: $499 · 2022: $790 · 2023: $895 · 2024: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $589.87 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $427.51 | 2019-2023 | Rexulti |
| Corium, LLC | $367.59 | 2022-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $364.71 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Neos Therapeutics, LP | $219.26 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.45 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.34 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $152.55 | 2021-2022 | |
| Rhodes Pharmaceuticals L.P. | $139.73 | 2019 | |
| Acadia Pharmaceuticals INC | $126.77 | 2022-2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $115.05 | 2022-2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $103.92 | 2019-2022 | |
| Tris Pharma INC | $103.88 | 2019-2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $99.89 | 2020-2021 | |
| Lundbeck LLC | $64.58 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $32.53 | 2023-2024 | Xelstrym |
| Vanda Pharmaceuticals INC. | $15.47 | 2023 | Hetlioz |
| Arbor Pharmaceuticals, INC. | $14.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.19 | 2019 | |
| Shire North American Group INC | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Banton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.